The dose–effect relationship of baclofen in alcohol dependence: A 1‐year cohort study
Objective Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Methods Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient‐month of treatment, the max...
Saved in:
| Published in | Human psychopharmacology Vol. 32; no. 4; pp. e2593 - n/a |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.07.2017
|
| Series | Human Psychopharmacology. Clinical and Experimental |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0885-6222 1099-1077 1099-1077 |
| DOI | 10.1002/hup.2593 |
Cover
| Abstract | Objective
Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence.
Methods
Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient‐month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient‐month into 3 categories (low dose: <90 mg/d, medium dose: 90–150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time‐varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC.
Results
One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]).
Conclusion
The relationship between dose of baclofen and favorable drinking outcome was U‐shaped, that is, was increased at low and high doses compared to medium doses. |
|---|---|
| AbstractList | Objective Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Methods Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90–150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. Results One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). Conclusion The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses. Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses. Objective Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Methods Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient‐month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient‐month into 3 categories (low dose: <90 mg/d, medium dose: 90–150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time‐varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. Results One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). Conclusion The relationship between dose of baclofen and favorable drinking outcome was U‐shaped, that is, was increased at low and high doses compared to medium doses. Objective Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Methods Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. Results One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). Conclusion The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses. Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence.OBJECTIVEOur aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence.Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC.METHODSTwo hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC.One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]).RESULTSOne hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]).The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses.CONCLUSIONThe relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses. |
| Author | Cottencin, Olivier Gautier, Sophie Bordet, Régis Pignon, Baptiste Labreuche, Julien Simioni, Nicolas Duhamel, Alain Auffret, Marine Deheul, Sylvie Rolland, Benjamin |
| Author_xml | – sequence: 1 givenname: Baptiste orcidid: 0000-0003-0526-3136 surname: Pignon fullname: Pignon, Baptiste email: baptistepignon@yahoo.fr organization: CHU Lille – sequence: 2 givenname: Julien surname: Labreuche fullname: Labreuche, Julien organization: Univ. Lille, CHU Lille, EA 2694 ‐ Santé publique : épidémiologie et qualité des soins – sequence: 3 givenname: Marine surname: Auffret fullname: Auffret, Marine organization: pharmacovigilance – addictovigilance, Univ. Lille – sequence: 4 givenname: Sophie surname: Gautier fullname: Gautier, Sophie organization: pharmacovigilance – addictovigilance, Univ. Lille – sequence: 5 givenname: Sylvie surname: Deheul fullname: Deheul, Sylvie organization: pharmacovigilance – addictovigilance, Univ. Lille – sequence: 6 givenname: Nicolas surname: Simioni fullname: Simioni, Nicolas organization: CHU Lille – sequence: 7 givenname: Olivier surname: Cottencin fullname: Cottencin, Olivier organization: Univ. Lille – sequence: 8 givenname: Régis surname: Bordet fullname: Bordet, Régis organization: pharmacovigilance – addictovigilance, Univ. Lille – sequence: 9 givenname: Alain surname: Duhamel fullname: Duhamel, Alain organization: Univ. Lille – sequence: 10 givenname: Benjamin surname: Rolland fullname: Rolland, Benjamin organization: pharmacovigilance – addictovigilance, Univ. Lille |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28517239$$D View this record in MEDLINE/PubMed https://hal.univ-lille.fr/hal-02369071$$DView record in HAL |
| BookMark | eNp10c1q3DAQB3BREppNWugTFEEvzcFbfawtq7clNN3CQnpIDj0JWR5hBa3lSnbK3vIIhbxhniTabJJCaU8CzU8jaf7H6KAPPSD0jpI5JYR96qZhzkrJX6EZJVIWlAhxgGakrsuiYowdoeOUrgnJNSJfoyNWl1QwLmfox2UHuA0J7m_vwFowI47g9ehCnzo34GBxo40PFnrseqy9CV3wuIUB-hZ6A5_xEtP7299b0BHvinHEaZza7Rt0aLVP8PZpPUFX518uz1bF-uLrt7PlujC85rywrakaIZgogbSUcLOAUugWKi0bYYWuSC2gZHxBQQpbVmbRMipqyhtua5M7nKDTfd9OezVEt9Fxq4J2arVcq90eYbySRNAbmu3HvR1i-DlBGtXGJQPe6x7ClBSVhFC2YFJm-uEveh2m2OefZEWlZKISVVbvn9TUbKB9uf95wBnM98DEkFIEq4wbH8c7Ru28okTtElQ5QbVL8M8TXw489_wHLfb0l_Ow_a9Tq6vvj_4BpLeo7w |
| CitedBy_id | crossref_primary_10_1007_s00213_018_4887_7 crossref_primary_10_2174_1573412919666230502124837 crossref_primary_10_1080_14656566_2017_1349098 crossref_primary_10_3389_fpsyt_2018_00367 crossref_primary_10_1097_YCO_0000000000000519 crossref_primary_10_1093_alcalc_agad090 crossref_primary_10_1016_j_alcohol_2025_03_002 crossref_primary_10_3389_fpsyt_2018_00385 crossref_primary_10_3389_fpsyt_2018_00708 crossref_primary_10_3389_fpsyt_2018_00417 crossref_primary_10_1016_j_therap_2019_06_002 crossref_primary_10_1016_j_neuropharm_2017_10_012 |
| Cites_doi | 10.1097/YIC.0000000000000054 10.1177/0269881114527362 10.1016/S0140-6736(07)61814-5 10.1111/j.1530-0277.2010.01273.x 10.2174/1381612821666150619091858 10.1097/JCP.0b013e3182860e84 10.2515/therapie/2010073 10.1111/j.1530-0277.1998.tb03892.x 10.1016/j.euroneuro.2016.10.006 10.1016/j.euroneuro.2013.02.006 10.1093/alcalc/37.5.504 10.1111/acer.12823 10.1016/j.euroneuro.2015.04.002 10.1111/j.1360-0443.2011.03752.x 10.1093/alcalc/agr017 10.1016/S0140-6736(07)61602-X 10.1093/alcalc/agh130 10.1371/journal.pone.0098062 10.1111/cns.12489 10.1016/j.euroneuro.2015.05.008 10.1016/j.biopsych.2012.10.020 10.1111/j.1360-0443.1988.tb00485.x 10.1016/j.pbb.2013.10.009 10.1177/0269881111408463 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 John Wiley & Sons, Ltd. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Copyright © 2017 John Wiley & Sons, Ltd. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 1XC |
| DOI | 10.1002/hup.2593 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1099-1077 |
| EndPage | n/a |
| ExternalDocumentID | oai_HAL_hal_02369071v1 28517239 10_1002_hup_2593 HUP2593 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABIVO ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EAD EAP EBC EBD EBS EJD EMB EMK EMOBN EPL EPS ESX F00 F01 F04 F5P FEDTE FUBAC G-S G.N GAKWD GNP GODZA H.X HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG AIQQE CITATION ESTFP CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 1XC |
| ID | FETCH-LOGICAL-c3833-fdc6b77275e0d103c4e57ade6a9b7f7a6087e52341e97f56c4d217813b3f8c833 |
| IEDL.DBID | DR2 |
| ISSN | 0885-6222 1099-1077 |
| IngestDate | Fri Sep 12 12:40:17 EDT 2025 Mon Sep 08 13:21:09 EDT 2025 Fri Jul 25 10:36:02 EDT 2025 Thu Apr 03 06:58:44 EDT 2025 Wed Oct 01 01:58:54 EDT 2025 Thu Apr 24 23:13:27 EDT 2025 Wed Jan 22 16:53:06 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | dose-effect relationship drug effect alcoholism baclofen treatment outcome off-label |
| Language | English |
| License | http://doi.wiley.com/10.1002/tdm_license_1.1 http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2017 John Wiley & Sons, Ltd. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3833-fdc6b77275e0d103c4e57ade6a9b7f7a6087e52341e97f56c4d217813b3f8c833 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0526-3136 0000-0002-5236-9083 0000-0003-3663-1405 0000-0003-3916-6422 0000-0002-8666-3635 |
| PMID | 28517239 |
| PQID | 1919927676 |
| PQPubID | 996344 |
| PageCount | 6 |
| ParticipantIDs | hal_primary_oai_HAL_hal_02369071v1 proquest_miscellaneous_1900124299 proquest_journals_1919927676 pubmed_primary_28517239 crossref_citationtrail_10_1002_hup_2593 crossref_primary_10_1002_hup_2593 wiley_primary_10_1002_hup_2593_HUP2593 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2017 2017-07-00 20170701 2017-07-01 |
| PublicationDateYYYYMMDD | 2017-07-01 |
| PublicationDate_xml | – month: 07 year: 2017 text: July 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Bognor Regis |
| PublicationSeriesTitle | Human Psychopharmacology. Clinical and Experimental |
| PublicationTitle | Human psychopharmacology |
| PublicationTitleAlternate | Hum Psychopharmacol |
| PublicationYear | 2017 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2010; 34 2002; 37 2015; 39 2011 2013; 23 2005; 40 2015b; 25 2014; 28 2012; 107 1998; 22 1999 2010; 65 2015; 25 2007; 370 2013; 33 2015a; 30 2013; 73 2015; 21 2013; 113 2011; 46 2016 1988; 83 2015 2014 2012; 26 2014; 9 2016; 26 2016; 22 Addolorato (10.1002/hup.2593-BIB0003|hup2593-cit-0004) 2007; 370 10.1002/hup.2593-BIB0004|hup2593-cit-0005 Sobell (10.1002/hup.2593-BIB0029|hup2593-cit-0030) 1988; 83 Brink (10.1002/hup.2593-BIB0031|hup2593-cit-0032) 2014; 28 Rolland (10.1002/hup.2593-BIB0022|hup2593-cit-0023) 2013; 33 Addolorato (10.1002/hup.2593-BIB0002|hup2593-cit-0003) 2011; 46 10.1002/hup.2593-BIB0010|hup2593-cit-0011 Reynaud (10.1002/hup.2593-BIB0020|hup2593-cit-0021) 2016 Mirijello (10.1002/hup.2593-BIB0018|hup2593-cit-0019) 2015; 21 Jaury (10.1002/hup.2593-BIB0016|hup2593-cit-0017) 2016 Beraha (10.1002/hup.2593-BIB0008|hup2593-cit-0009) 2016; 26 Hill (10.1002/hup.2593-BIB0014|hup2593-cit-0015) 1998; 22 Müller (10.1002/hup.2593-BIB0019|hup2593-cit-0020) 2015; 25 Addolorato (10.1002/hup.2593-BIB0001|hup2593-cit-0002) 2002; 37 Mann (10.1002/hup.2593-BIB0017|hup2593-cit-0018) 2013; 73 Harrington (10.1002/hup.2593-BIB0013|hup2593-cit-0014) 1999 Tabakoff (10.1002/hup.2593-BIB0030|hup2593-cit-0031) 2013; 113 Rolland (10.1002/hup.2593-BIB0023|hup2593-cit-0024) 2010; 65 Imbert (10.1002/hup.2593-BIB0015|hup2593-cit-0016) 2015; 39 10.1002/hup.2593-BIB0028|hup2593-cit-0029 Elm (10.1002/hup.2593-BIB0032|hup2593-cit-0033) 2007; 370 Chick (10.1002/hup.2593-BIB0009|hup2593-cit-0010) 2012; 26 Rolland (10.1002/hup.2593-BIB0024|hup2593-cit-0025) 2015b; 25 Rolland (10.1002/hup.2593-BIB0021|hup2593-cit-0022) 2012; 107 Gual (10.1002/hup.2593-BIB0012|hup2593-cit-0013) 2013; 23 Ameisen (10.1002/hup.2593-BIB0006|hup2593-cit-0007) 2005; 40 Rolland (10.1002/hup.2593-BIB0027|hup2593-cit-0028) 2015a; 30 Garbutt (10.1002/hup.2593-BIB0011|hup2593-cit-0012) 2010; 34 10.1002/hup.2593-BIB0007|hup2593-cit-0008 Rolland (10.1002/hup.2593-BIB0026|hup2593-cit-0027) 2016; 22 Rolland (10.1002/hup.2593-BIB0025|hup2593-cit-0026) 2014; 9 |
| References_xml | – year: 2011 – volume: 73 start-page: 706 issue: 8 year: 2013 end-page: 713 article-title: Extending the treatment options in alcohol dependence: A randomized controlled study of as‐needed nalmefene publication-title: Biological Psychiatry – volume: 25 start-page: 1631 issue: 10 year: 2015b end-page: 1636 article-title: Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation publication-title: European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology – volume: 26 start-page: 205 issue: 2 year: 2012 end-page: 212 article-title: Substitution therapy for alcoholism: Time for a reappraisal? publication-title: Journal of Psychopharmacology (Oxford, England) – volume: 370 start-page: 1915 issue: 9603 year: 2007 end-page: 1922 article-title: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol‐dependent patients with liver cirrhosis: Randomised, double‐blind controlled study publication-title: The Lancet – volume: 26 start-page: 1950 issue: 12 year: 2016 end-page: 1959 article-title: Efficacy and safety of high‐dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double‐blind controlled trial publication-title: European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology – volume: 370 start-page: 1453 issue: 9596 year: 2007 end-page: 1457 article-title: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies publication-title: Lancet (London, England) – volume: 113 start-page: 20 year: 2013 end-page: 37 article-title: The neurobiology of alcohol consumption and alcoholism: An integrative history publication-title: Pharmacology, Biochemistry, and Behavior – volume: 33 start-page: 280 issue: 2 year: 2013 end-page: 281 article-title: Baclofen for alcohol‐dependence: Anticraving or partial substitution? publication-title: Journal of Clinical Psychopharmacology – volume: 22 start-page: 25 issue: 1 year: 2016 end-page: 37 article-title: Pharmacotherapy for alcohol dependence: The 2015 recommendations of the French alcohol society, issued in partnership with the European Federation of Addiction Societies publication-title: CNS Neuroscience & Therapeutics – volume: 30 start-page: 49 issue: 1 year: 2015a end-page: 53 article-title: Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high‐dose baclofen: A comparative cohort study publication-title: International Clinical Psychopharmacology – volume: 34 start-page: 1849 issue: 11 year: 2010 end-page: 1857 article-title: Efficacy and safety of baclofen for alcohol dependence: A randomized, double‐blind, placebo‐controlled trial publication-title: Alcoholism: Clinical and Experimental Research – year: 2016 – volume: 25 start-page: 1167 issue: 8 year: 2015 end-page: 1177 article-title: High‐dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo‐controlled trial publication-title: European Neuropsychopharmacology – year: 2014 – volume: 83 start-page: 393 issue: 4 year: 1988 end-page: 402 article-title: Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations publication-title: British Journal of Addiction – volume: 28 start-page: 733 issue: 8 year: 2014 end-page: 744 article-title: Long‐term efficacy, tolerability and safety of nalmefene as‐needed in patients with alcohol dependence: A 1‐year, randomised controlled study publication-title: Journal of Psychopharmacology (Oxford, England) – volume: 23 start-page: 1432 issue: 11 year: 2013 end-page: 1442 article-title: A randomised, double‐blind, placebo‐controlled, efficacy study of nalmefene, as‐needed use, in patients with alcohol dependence publication-title: European Neuropsychopharmacology – volume: 46 start-page: 312 issue: 3 year: 2011 end-page: 317 article-title: Dose–response effect of baclofen in reducing daily alcohol Intake in alcohol dependence: Secondary analysis of a randomized, double‐blind, placebo‐controlled trial publication-title: Alcohol and Alcoholism – volume: 37 start-page: 504 issue: 5 year: 2002 end-page: 508 article-title: Baclofen efficacy in reducing alcohol craving and Intake: A preliminary double‐blind randomized controlled study publication-title: Alcohol and Alcoholism – volume: 39 start-page: 1602 issue: 9 year: 2015 end-page: 1608 article-title: Anticraving effect of baclofen in alcohol‐dependent patients publication-title: Alcoholism: Clinical and Experimental Research – volume: 40 start-page: 147 issue: 2 year: 2005 end-page: 150 article-title: Complete and prolonged suppression of symptoms and consequences of alcohol‐dependence using high‐dose baclofen: A self‐case report of a physician publication-title: Alcohol and Alcoholism – volume: 65 start-page: 511 issue: 6 year: 2010 end-page: 518 article-title: [Un dispositif de prescriptions hors‐AMM: Exemple du baclofène] A system of prescriptions without drug approval: Example of baclofen publication-title: Thérapie – volume: 21 start-page: 3367 issue: 23 year: 2015 end-page: 3372 article-title: GABAB agonists for the treatment of alcohol use disorder publication-title: Current Pharmaceutical Design – volume: 9 issue: 6 year: 2014 article-title: Off‐label baclofen prescribing practices among French alcohol specialists: Results of a national online survey publication-title: PloS One – year: 2015 – year: 1999 – volume: 22 start-page: 935 issue: 4 year: 1998 end-page: 940 article-title: Prevalence of alcohol dependence and abuse in general practice publication-title: Alcoholism: Clinical and Experimental Research – volume: 107 start-page: 848 issue: 4 year: 2012 end-page: 849 article-title: Alcohol‐dependence: The current French craze for baclofen publication-title: Addiction – volume: 30 start-page: 49 issue: 1 year: 2015a ident: 10.1002/hup.2593-BIB0027|hup2593-cit-0028 article-title: Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: A comparative cohort study publication-title: International Clinical Psychopharmacology doi: 10.1097/YIC.0000000000000054 – volume: 28 start-page: 733 issue: 8 year: 2014 ident: 10.1002/hup.2593-BIB0031|hup2593-cit-0032 article-title: Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study publication-title: Journal of Psychopharmacology (Oxford, England) doi: 10.1177/0269881114527362 – volume: 370 start-page: 1915 issue: 9603 year: 2007 ident: 10.1002/hup.2593-BIB0003|hup2593-cit-0004 article-title: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study publication-title: The Lancet doi: 10.1016/S0140-6736(07)61814-5 – ident: 10.1002/hup.2593-BIB0004|hup2593-cit-0005 – ident: 10.1002/hup.2593-BIB0010|hup2593-cit-0011 – volume: 34 start-page: 1849 issue: 11 year: 2010 ident: 10.1002/hup.2593-BIB0011|hup2593-cit-0012 article-title: Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/j.1530-0277.2010.01273.x – volume: 21 start-page: 3367 issue: 23 year: 2015 ident: 10.1002/hup.2593-BIB0018|hup2593-cit-0019 article-title: GABAB agonists for the treatment of alcohol use disorder publication-title: Current Pharmaceutical Design doi: 10.2174/1381612821666150619091858 – ident: 10.1002/hup.2593-BIB0028|hup2593-cit-0029 – volume: 33 start-page: 280 issue: 2 year: 2013 ident: 10.1002/hup.2593-BIB0022|hup2593-cit-0023 article-title: Baclofen for alcohol-dependence: Anticraving or partial substitution? publication-title: Journal of Clinical Psychopharmacology doi: 10.1097/JCP.0b013e3182860e84 – volume: 65 start-page: 511 issue: 6 year: 2010 ident: 10.1002/hup.2593-BIB0023|hup2593-cit-0024 article-title: [Un dispositif de prescriptions hors-AMM: Exemple du baclofène] A system of prescriptions without drug approval: Example of baclofen publication-title: Thérapie doi: 10.2515/therapie/2010073 – volume: 22 start-page: 935 issue: 4 year: 1998 ident: 10.1002/hup.2593-BIB0014|hup2593-cit-0015 article-title: Prevalence of alcohol dependence and abuse in general practice publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/j.1530-0277.1998.tb03892.x – volume-title: A randomized, double blind, placebo-controlled efficacy study of high-dose baclofen in alcohol dependent patients: The ‘ALPADIR’ study (oral communication) year: 2016 ident: 10.1002/hup.2593-BIB0020|hup2593-cit-0021 – volume-title: Cinical efficacy study of high dose baclofen in reducing alcohol consumption (oral communication) year: 2016 ident: 10.1002/hup.2593-BIB0016|hup2593-cit-0017 – volume-title: The placebo effect: An interdisciplinary exploration year: 1999 ident: 10.1002/hup.2593-BIB0013|hup2593-cit-0014 – volume: 26 start-page: 1950 issue: 12 year: 2016 ident: 10.1002/hup.2593-BIB0008|hup2593-cit-0009 article-title: Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial publication-title: European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology doi: 10.1016/j.euroneuro.2016.10.006 – volume: 23 start-page: 1432 issue: 11 year: 2013 ident: 10.1002/hup.2593-BIB0012|hup2593-cit-0013 article-title: A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence publication-title: European Neuropsychopharmacology doi: 10.1016/j.euroneuro.2013.02.006 – volume: 37 start-page: 504 issue: 5 year: 2002 ident: 10.1002/hup.2593-BIB0001|hup2593-cit-0002 article-title: Baclofen efficacy in reducing alcohol craving and Intake: A preliminary double-blind randomized controlled study publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/37.5.504 – volume: 39 start-page: 1602 issue: 9 year: 2015 ident: 10.1002/hup.2593-BIB0015|hup2593-cit-0016 article-title: Anticraving effect of baclofen in alcohol-dependent patients publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/acer.12823 – volume: 25 start-page: 1167 issue: 8 year: 2015 ident: 10.1002/hup.2593-BIB0019|hup2593-cit-0020 article-title: High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial publication-title: European Neuropsychopharmacology doi: 10.1016/j.euroneuro.2015.04.002 – volume: 107 start-page: 848 issue: 4 year: 2012 ident: 10.1002/hup.2593-BIB0021|hup2593-cit-0022 article-title: Alcohol-dependence: The current French craze for baclofen publication-title: Addiction doi: 10.1111/j.1360-0443.2011.03752.x – volume: 46 start-page: 312 issue: 3 year: 2011 ident: 10.1002/hup.2593-BIB0002|hup2593-cit-0003 article-title: Dose-response effect of baclofen in reducing daily alcohol Intake in alcohol dependence: Secondary analysis of a randomized, double-blind, placebo-controlled trial publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/agr017 – volume: 370 start-page: 1453 issue: 9596 year: 2007 ident: 10.1002/hup.2593-BIB0032|hup2593-cit-0033 article-title: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(07)61602-X – volume: 40 start-page: 147 issue: 2 year: 2005 ident: 10.1002/hup.2593-BIB0006|hup2593-cit-0007 article-title: Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/agh130 – volume: 9 issue: 6 year: 2014 ident: 10.1002/hup.2593-BIB0025|hup2593-cit-0026 article-title: Off-label baclofen prescribing practices among French alcohol specialists: Results of a national online survey publication-title: PloS One doi: 10.1371/journal.pone.0098062 – volume: 22 start-page: 25 issue: 1 year: 2016 ident: 10.1002/hup.2593-BIB0026|hup2593-cit-0027 article-title: Pharmacotherapy for alcohol dependence: The 2015 recommendations of the French alcohol society, issued in partnership with the European Federation of Addiction Societies publication-title: CNS Neuroscience & Therapeutics doi: 10.1111/cns.12489 – volume: 25 start-page: 1631 issue: 10 year: 2015b ident: 10.1002/hup.2593-BIB0024|hup2593-cit-0025 article-title: Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation publication-title: European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology doi: 10.1016/j.euroneuro.2015.05.008 – ident: 10.1002/hup.2593-BIB0007|hup2593-cit-0008 – volume: 73 start-page: 706 issue: 8 year: 2013 ident: 10.1002/hup.2593-BIB0017|hup2593-cit-0018 article-title: Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene publication-title: Biological Psychiatry doi: 10.1016/j.biopsych.2012.10.020 – volume: 83 start-page: 393 issue: 4 year: 1988 ident: 10.1002/hup.2593-BIB0029|hup2593-cit-0030 article-title: Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations publication-title: British Journal of Addiction doi: 10.1111/j.1360-0443.1988.tb00485.x – volume: 113 start-page: 20 year: 2013 ident: 10.1002/hup.2593-BIB0030|hup2593-cit-0031 article-title: The neurobiology of alcohol consumption and alcoholism: An integrative history publication-title: Pharmacology, Biochemistry, and Behavior doi: 10.1016/j.pbb.2013.10.009 – volume: 26 start-page: 205 issue: 2 year: 2012 ident: 10.1002/hup.2593-BIB0009|hup2593-cit-0010 article-title: Substitution therapy for alcoholism: Time for a reappraisal? publication-title: Journal of Psychopharmacology (Oxford, England) doi: 10.1177/0269881111408463 |
| SSID | ssj0009909 |
| Score | 2.2174914 |
| Snippet | Objective
Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence.
Methods
Two hundred two patients with alcohol... Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Two hundred two patients with alcohol dependence, who... Objective Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Methods Two hundred two patients with alcohol... Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence.OBJECTIVEOur aim is to study the relationship between... |
| SourceID | hal proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e2593 |
| SubjectTerms | Adult Alcohol Deterrents - administration & dosage Alcohol Drinking Alcohol use alcoholism Alcoholism - drug therapy Baclofen Baclofen - administration & dosage Cognitive science Cohort analysis Dose-Response Relationship, Drug dose–effect relationship Drinking behavior Drug dependence drug effect Female Follow-Up Studies Humans Male Middle Aged off‐label Proportional Hazards Models Treatment Outcome |
| Title | The dose–effect relationship of baclofen in alcohol dependence: A 1‐year cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhup.2593 https://www.ncbi.nlm.nih.gov/pubmed/28517239 https://www.proquest.com/docview/1919927676 https://www.proquest.com/docview/1900124299 https://hal.univ-lille.fr/hal-02369071 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1099-1077 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0009909 issn: 0885-6222 databaseCode: ABDBF dateStart: 19860901 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0885-6222 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1099-1077 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009909 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZpeumlTZs-tkmDGsL2Em_8lOzeNm2WpbRhKVlI6cFI8pgNDfayj8L2lJ8QyD_ML-mMZXtJH1B6MnjGtizNSN9Io0-MHfjKYA-glOObJHBCRLBOHAM4MtJChNoIAzTf8elUDMfhh_PovM6qpL0wlh-inXAjz6j6a3JwpedHa9LQyXLaQ-xORJ9eEFUrtJ_XzFHYySYWQEaOwDGw4Z11_aPmwTsj0b0J5UH-DjLvYtZq0Bk8Yl-b4tpck2-95UL3zI9fmBz_73-22MMai_K-NZ7HbAOKJ6w7smTWq0N-tt6bNT_kXT5a01yvttkXFPOsnMPt1Y3NCuGzJrNucjHlZc61MpdlDgW_KLiyZ_Hy5tRdA295n3u3V9crdDZOwtmCV2y3T9l4cHL2bujUBzU4BgPcwMkzIzTCdBmBm3luYEKIpMpAqETLXCrhxhIw4g09SGQeCRNmGAnFXqCDPDb4hmdssygLeME4wkm0HuOCdk0YahRj2JwHrolBQCyTDnvTNFpqahZzOkzjMrX8y36K9ZhSPXbY61Zzapk7_qCzj-3eiolqe9j_mNI9YtZPEH999zpstzGLtHbweYphbpL4UkiB32nF6Jq03qIKKJekQ2CSBvwOe27Nqf2Uj0hX-gFKupVR_LWI6XA8ouvLf1XcYQ98gh5VSvEu21zMlvAKgdNC77H7_eP3x4O9ylV-AvL1F5M |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB615QAX3o-FAgah5dJs87QTOK2AKsC2WqFdqZWQIttxtBVVstoH0nLqT0DiH_aXMBNvsioPCXGKlJkkjj1jf2OPPwO88KXGHkBKx9dJ4ISIYJ04NsYRkeI8VJprQ_Mdh0c8HYcfjqPjLXjd7IWx_BDthBt5Rt1fk4PThPT-hjV0spz2ELwH23CFlufIK99-2nBHYTebWAgZORxHwYZ51vX3mycvjUXbE8qE_B1mXkat9bBzcAM-NwW22SZfesuF6ulvv3A5_ucf3YTrazjK-tZ-bsGWKW9Dd2j5rFd7bLTZnjXfY1023DBdr-7ACYpZXs3NxfkPmxjCZk1y3eR0yqqCKanPqsKU7LRk0h7Hy5qDd7V5xfrMuzj_vkJ_YyScLVhNeHsXxgfvRm9SZ31Wg6Mxxg2cItdcIVIXkXFzzw10aCIhc8NlokQhJHdjYTDoDT2TiCLiOswxGIq9QAVFrPEN92CnrErzABgiSjQg7Rrl6jBUKMbIuQhcHRtuYpF04GXTapleE5nTeRpnmaVg9jOsx4zqsQPPWs2pJe_4g85zbPhWTGzbaX-Q0T0i108Qgn31OrDb2EW29vF5hpFukviCC47facXonbTkIktTLUmH8CSN-R24b-2p_ZSPYFf4AUq6tVX8tYhZOh7S9eG_Kj6Fq-nocJAN3h99fATXfEIidYbxLuwsZkvzGHHUQj2p_eUnhA8aPQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZNCqWXvh-bpK1ayvYSb_yQJbu3pe2ybdOwlCyk9CAkWWZDgr3so7A55ScU8g_zSzJj2V7SB5SeDJ6xJUsz0jfy6BMhr0NlYARQygtNGnkMEKyXJNZ6ItacM224sbje8eWAD8fs01F8VGdV4l4Yxw_RLrihZ1TjNTr4NMv31qShk-W0B9g92iA3GYfgCgHR1zV1FIyyqUOQscdhEmyIZ_1wr3ny2lS0McFEyN9R5nXQWs06g7vke1Nfl2xy0lsudM-c_ULl-H8fdI_cqcEo7TvruU9u2OIB6Y4cm_Vqlx6uN2fNd2mXjtY816uH5BuIaVbO7eX5hUsLobMmtW5yPKVlTrUyp2VuC3pcUOUO46XNsbvGvqV9Glye_1yBt1EUzha0ort9RMaDD4fvhl59UoNnIMKNvDwzXANOF7H1s8CPDLOxUJnlKtUiF4r7ibAQ8rLApiKPuWEZhEJJEOkoTwy84THZLMrCPiUU8CSYj_Gt9g1jGsQQN-eRbxLLbSLSDnnTdJo0NY05nqZxKh0BcyihHSW2Y4e8bDWnjrrjDzqvoN9bMXJtD_v7Eu8htX4KAOxH0CE7jVnI2sPnEuLcNA0FFxzKacXgm_jDRRW2XKIOokmc8TvkiTOntqgQoK4II5B0K6P4axXlcDzC69a_Kr4gt0bvB3L_48HnbXI7RBhSpRfvkM3FbGmfAYha6OeVt1wBKwQY7A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+dose-effect+relationship+of+baclofen+in+alcohol+dependence%3A+A+1-year+cohort+study&rft.jtitle=Human+psychopharmacology&rft.au=Pignon%2C+Baptiste&rft.au=Labreuche%2C+Julien&rft.au=Auffret%2C+Marine&rft.au=Gautier%2C+Sophie&rft.date=2017-07-01&rft.eissn=1099-1077&rft.volume=32&rft.issue=4&rft_id=info:doi/10.1002%2Fhup.2593&rft_id=info%3Apmid%2F28517239&rft.externalDocID=28517239 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-6222&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-6222&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-6222&client=summon |